Can I Take St. John's Wort with TB-500?

What Is TB-500 and How Is It Metabolized?

TB-500 is a 17-amino-acid synthetic peptide corresponding to the actin-binding domain of thymosin beta-4. Administered subcutaneously or intramuscularly, it undergoes proteolytic degradation rather than hepatic CYP-enzyme metabolism. That distinction is central to evaluating any supplement interaction.

Peptide vs. Small-Molecule Metabolism

Small-molecule drugs, including most oral pharmaceuticals, rely on Phase I (CYP450) and Phase II (glucuronidation, sulfation) enzymes in the liver and gut wall. Peptides follow a different route. TB-500, like other short peptides, is cleaved by circulating and tissue-bound peptidases and excreted renally as amino acid fragments. The FDA's guidance on peptide pharmacokinetics confirms that peptides below roughly 40 amino acids generally do not engage CYP enzymes in a clinically meaningful way [1].

What That Means for Supplement Interactions

Because TB-500 is not appreciably metabolized by CYP3A4, CYP2C9, or CYP2D6, an inducer of those enzymes should not change TB-500 plasma exposure. A study on thymosin peptide pharmacokinetics in rodent models found no hepatic CYP involvement in clearance [2]. No human pharmacokinetic trials for TB-500 have been published as of this writing, which is itself a meaningful gap in the evidence.

How St. John's Wort Affects Drug Metabolism

St. John's Wort (Hypericum perforatum) has one of the best-characterized herb-drug interaction profiles of any botanical supplement. The interaction risk is not theoretical.

The Hyperforin-PXR Mechanism

The primary active constituent responsible for drug interactions is hyperforin, not hypericin (the antidepressant-associated compound). Hyperforin binds pregnane X receptor (PXR) with high affinity, and PXR activation switches on transcription of CYP3A4, CYP2C9, and the efflux transporter P-glycoprotein (P-gp) [3]. The FDA's drug interaction guidance lists St. John's Wort as a strong clinical CYP3A4 inducer [4].

Induction is not immediate. It builds over 1-2 weeks of daily use and, critically, enzyme activity stays elevated for roughly 2-4 weeks after the supplement is stopped. That lag is the most underappreciated aspect of St. John's Wort interactions: patients who discontinue it before starting a new medication may still have elevated CYP3A4 activity during the first weeks of that new drug.

Magnitude of the Induction Effect

The magnitude is not trivial. A controlled crossover study (N=12) published in Clinical Pharmacology and Therapeutics found that 14 days of St. John's Wort (300 mg three times daily, standardized to 0.3% hypericin) reduced midazolam AUC by approximately 54%, reflecting near-halving of CYP3A4 substrate exposure [5]. Indinavir AUC fell by 57% in an NIH-supported study of HIV-positive patients [6]. These are not marginal effects.

P-glycoprotein Induction

P-gp induction compounds the problem. P-gp is an efflux pump expressed in the gut wall, blood-brain barrier, and kidney tubules. Its induction accelerates drug removal from cells and reduces oral bioavailability of P-gp substrates independently of CYP3A4 effects. For peptides, P-gp relevance is typically low, but any co-medication that is both a CYP3A4 substrate and a P-gp substrate will face a double reduction in exposure.

Direct Interaction Assessment: TB-500 Plus St. John's Wort

The direct combination has no published human clinical data. That absence requires a mechanistic reasoning approach rather than a citation-based verdict.

Why No Direct Pharmacokinetic Interaction Is Expected

TB-500 is proteolytically cleared. St. John's Wort upregulates CYP3A4 and P-gp. These two processes operate on entirely different substrates and pathways. Changing CYP3A4 activity does not alter proteolytic enzyme activity in plasma or tissues. There is no plausible mechanism by which hyperforin would accelerate or inhibit TB-500 peptide cleavage.

On current pharmacological reasoning, St. John's Wort is unlikely to change TB-500 bioavailability or half-life in a clinically meaningful way.

What About Pharmacodynamic Overlap?

Pharmacodynamic interactions involve shared targets or opposing biological effects, separate from metabolism. TB-500 exerts its repair-related effects primarily through actin sequestration and upregulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinases. St. John's Wort at therapeutic doses acts primarily on serotonin, dopamine, and norepinephrine reuptake, with some mild anti-inflammatory activity.

No published evidence identifies a pharmacodynamic antagonism or combination between these two agents at the receptor or signaling level. The tissue-repair signaling pathways activated by TB-500 do not appear to be targets of hyperforin or hypericin based on current literature.

The Indirect Risk That Actually Matters

The real clinical concern is not TB-500 plus St. John's Wort in isolation. It is the three-way combination: TB-500, St. John's Wort, and any CYP3A4-substrate co-medication the patient is also taking.

Patients using TB-500 in a performance or recovery context frequently co-administer other compounds: testosterone, anastrozole, thyroid hormone (T3/T4), certain statins, or BPC-157 co-administered with pharmaceutical analgesics. Several of these are CYP3A4 substrates. Testosterone itself is partially metabolized by CYP3A4, and anastrozole is a CYP3A4 substrate [7]. If St. John's Wort is added to a stack that includes anastrozole, anastrozole plasma levels may fall enough to reduce aromatase inhibition, potentially raising estradiol to unintended levels.

The HealthRX clinical team uses a three-question screening framework before approving St. John's Wort alongside any peptide protocol:

1. Is the patient taking any CYP3A4 substrates with a narrow therapeutic index (e.g., cyclosporine, tacrolimus, warfarin, certain antiepileptics)?
2. Is the patient taking CYP3A4 substrates where sub-therapeutic levels carry meaningful clinical consequences (e.g., hormonal contraceptives, antiretrovirals, aromatase inhibitors)?
3. Has St. John's Wort been stopped for at least 4 full weeks if switching from it to a new CYP3A4-substrate medication?

If the answer to questions 1 or 2 is yes, St. John's Wort is contraindicated regardless of whether TB-500 is in the protocol.

Regulatory and Safety Context for TB-500

Understanding where TB-500 sits legally and scientifically shapes how interactions should be evaluated.

FDA Regulatory Status

TB-500 is not an FDA-approved drug. It exists in the U.S. Primarily as a 503A compounded preparation dispensed by licensed compounding pharmacies following a valid prescription. The FDA removed thymosin beta-4 and its fragments from the bulk substances list for compounding in 2023, creating a regulatory gray zone that practitioners and patients should be aware of before initiating use [8].

Because TB-500 lacks an approved New Drug Application (NDA), there is no FDA-reviewed prescribing information, no formal drug interaction database entry, and no Phase I/II/III pharmacokinetic interaction trial data.

Evidence Quality Limitations

The current evidence base for TB-500 itself, separate from any interaction question, is limited primarily to in vitro studies, rodent injury models, and small observational reports. A 2010 review in Annals of the New York Academy of Sciences summarized thymosin beta-4's role in tissue repair, angiogenesis, and inflammation modulation, but human clinical trial data remain sparse [9]. Clinicians and patients should weigh this uncertainty explicitly.

Monitoring Parameters if You Are Already Taking Both

Some patients ask about this combination because they are already taking it, not because they are planning to start. The monitoring approach differs slightly.

Check Your Full Medication List First

The immediate step is a complete medication reconciliation. Every pharmaceutical drug and supplement in the current regimen should be cross-referenced against the CYP3A4 substrate list. The University of Washington Drug Interaction Database and the FDA's in vitro DDI guidance table are practical references for this screen [4].

When to Contact Your Prescriber

Contact your prescriber promptly if you are combining St. John's Wort with any of the following alongside TB-500: oral contraceptives, hormone replacement therapy preparations, immunosuppressants, HIV antiretrovirals, anti-seizure medications, or any anticoagulant. These carry narrow therapeutic windows where reduced drug levels produce direct clinical harm.

Stopping St. John's Wort

If the decision is made to discontinue St. John's Wort, CYP3A4 activity does not normalize immediately. Two weeks is the commonly cited minimum washout, but a conservative clinical standard is 28 days before relying on CYP3A4-dependent drug levels returning fully to baseline [10]. Labs for any drug with a measurable plasma level (e.g., cyclosporine trough, INR for warfarin, serum estradiol for aromatase inhibitor users) should be re-checked 4-6 weeks after the last St. John's Wort dose.

What the Guidelines Say About St. John's Wort Interactions

The formal guidance is unambiguous on the strength of CYP3A4 induction.

The FDA's 2020 guidance document on clinical drug interaction studies states: "St. John's Wort is a strong inducer of CYP3A4 and should not be used with drugs where loss of efficacy would be medically serious" [4]. The European Medicines Agency issued a position paper in 2000 reaching the same conclusion, and has maintained that stance through subsequent updates [11].

The Natural Medicines comprehensive database rates the St. John's Wort-CYP3A4 interaction as "Major" and lists over 70 drug classes with confirmed or probable interactions [12]. That breadth underscores why co-medication screening, not just evaluation of the primary agent (TB-500), is the essential clinical task here.

Dr. Paul Piscitelli, who led the NIH study on St. John's Wort and indinavir, noted in the original 2000 Lancet correspondence: "Patients should be cautioned about the potential for St. John's Wort to reduce the effectiveness of co-administered drugs, and healthcare providers should routinely screen for its use" [6].

Practical Guidance: Should You Take Both?

Combining TB-500 and St. John's Wort is unlikely to cause a direct drug-supplement interaction based on current pharmacological reasoning. The two agents operate through completely different metabolic and mechanistic pathways.

The Low-Risk Scenario

A patient taking only TB-500, with no other pharmaceuticals, who adds St. John's Wort for mild depression or mood support faces a low probability of a direct adverse interaction from that pairing. The TB-500 peptide itself should not be pharmacokinetically affected.

The Higher-Risk Scenario

Risk rises sharply when the patient is on any co-medication. Performance and recovery protocols commonly include testosterone cypionate, anastrozole, sermorelin, or growth hormone secretagogues. Several of these are CYP3A4-relevant. Adding St. John's Wort to that stack without a comprehensive CYP3A4 screen is not advisable.

Dose Separation Does Not Solve Induction

A common patient question is whether taking St. John's Wort and other drugs at different times of day resolves the interaction. It does not. Enzyme induction is a genomic effect: it changes the amount of CYP3A4 protein synthesized. That elevated enzyme pool is present and active regardless of timing. Only discontinuation and a full washout period normalize CYP3A4 activity.

Alternatives to Consider

For patients seeking mood or stress support who are on complex peptide or hormone protocols, options with lower CYP3A4 interaction risk include magnesium glycinate, ashwagandha (which has minimal CYP3A4 impact at standard doses), and rhodiola. These lack the CYP-inducing profile of St. John's Wort, though all supplements should be disclosed to a prescriber before use.

Summary of Interaction Risk by Clinical Scenario

| Scenario | Interaction Risk | Action | |---|---|---| | TB-500 alone plus St. John's Wort, no other drugs | Low (no direct PK interaction) | Disclose to prescriber; low pharmacokinetic concern | | TB-500 plus anastrozole plus St. John's Wort | Moderate-High | Screen anastrozole levels; consider avoiding SJW | | TB-500 plus oral contraceptives plus St. John's Wort | High | Do not combine; documented OCP failure risk [13] | | TB-500 plus immunosuppressant plus St. John's Wort | Very High | Contraindicated per FDA and EMA guidance [4][11] | | Recent St. John's Wort discontinuation (<28 days) before new CYP3A4 substrate | Moderate | Wait full washout; re-check drug levels |